Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The heart and estrogen/progestin replacement study

Annals of Internal Medicine

Volumn 135, Issue 7, 2001, Pages 493-501

  Simon, J A ^a   Hunninghake, D B ^a   Agarwal, S K ^a   Lin, F ^a   Cauley, J A ^a   Ireland, C C ^a   Pickar, J H ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AGED; ARTICLE; BILIARY TRACT SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; GALLBLADDER DISEASE; GALLSTONE; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0035797873     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-7-200110020-00008     Document Type: Article

References (40)

1. Serum ascorbic acid and gallbladder disease prevalence among US adults: The Third National Health and Nutrition Examination Survey (NHANES III)
2. Epidemiology and natural history of gallstone disease
3. Estrogen replacement therapy and gallbladder disease in postmenopausal women
4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
5. Hormone replacement therapy for secondary prevention of coronary heart disease
6. Robust inference for the Cox proportional hazards model
7. Confidence intervals for the number needed to treat
8. Ascorbic acid supplement use and the prevalence of gallbladder disease
9. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program
10. Increased incidence of symptomatic cholesterol cholelithiasis in perimenopausal women receiving estrogen replacement therapy: A retrospective study
11. Association of a history of gallbladder disease with a reduced concentration of high-density-lipoprotein cholesterol
12. Increased risk of cholecystectomy in usets of supplemental estrogen
13. Oral contraceptives and non-contraceptive oestrogens in the risk of gallstone disease requiring surgery
14. Postmenopausal hormone use and cholecystectomy in a large prospective study
15. Non-contraceptive estrogen use and the risk of gallstone disease in women
16. Gall stones in a Danish population: Fertility period, pregnancies, and exogenous female sex hormones
17. Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project
18. Estrogen-induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma
19. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
20. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
21. Gallstones: Pathogenesis
22. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism
23. Pathogenesis and treatment of gallstones
24. Sex steroid hormone receptors and human gallbladder motility in vitro
25. Cholelithiasis induced in the Syrian hamster: Evidence for an intramucinous nucleating process and down regulation of cholesterol 7 alpha-hydroxylase (CYP7) gene by medroxyprogesterone
26. Pharmacokinetic and pharmacologic variation between different estrogen products
27. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women
28. Contributions of obesity and weight loss to gallstone disease
29. Weight, diet, and the risk of symptomatic gallstones in middle-aged women
30. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
31. Gallstones laparoscopic cholecystectomy
32. Moderate alcohol intake reduces bile cholesterol saturation and raises HDL cholesterol
33. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile
34. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation
35. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia
36. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor
37. The epidemiology of gallbladder disease: Observations in the Framingham Study
38. A prospective study of symptomatic gallstones in women: Relation with oral contraceptives and other risk factors